A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
A Randomized, Double-blind, Multicenter Phase III Study of Brivanib Versus Placebo as Adjuvant Therapy to Trans-Arterial Chemo-Embolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (The BRISK TA Study)
The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com.
Inclusion Criteria:
Exclusion criteria:
Capital Federal, Buenos Aires C1405BCK, Argentina
Kashiwa-shi, Chiba 277-0882, Japan
Ogaki-shi, Gifu 5038502, Japan
Kure-shi, Hiroshima 7370023, Japan
Kawasaki-shi, Kanagawa 2138587, Japan
Higashinari-ku, Osaka 5378511, Japan
Sunto-gun, Shizuoka 411-8777, Japan
Chuo-ku, Tokyo 104-0045, Japan
Minato-ku, Tokyo 105-0001, Japan
Musashino-shi, Tokyo 180-0023, Japan
Nishinomiya-shi, 6638501, Japan
Kyunggi-do, 463-707, South Korea